Panacea Biotec Limited — Updates, 03-06-2025: Press Release

Panacea Biotec has announced a board meeting to review the financial results for the quarter and half-year. The company commercialized its homegrown adjuvant, EmulsiPan, now part of the CEPI Adjuvant Library. EmulsiPan boosts vaccine efficacy and dose-sparing, tapping into the $4.8 billion global adjuvant market. This ready-to-use, license-free adjuvant strengthens Panacea’s innovation edge and commitment to affordable vaccine solutions globally.